Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
Status:
Completed
Trial end date:
2020-04-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find a new way to treat Acute Myeloid Leukemia (AML),
Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML). All the drugs are
used to treat AML and MDS but are not usually combined together. The investigators are
looking at both the safety and Efficacy of each combination.
Phase:
Phase 2
Details
Lead Sponsor:
Fox Chase Cancer Center M.D. Anderson Cancer Center
Collaborators:
Leukemia SPORE M.D. Anderson Cancer Center TEVA Teva Pharmaceuticals USA